secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0001193125-24-183292
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene appoints Ron Cooper as CEO, promotes Raj Pruthi to CMO; Hanson departs as planned
--------------------------------------------------------------------------------

- Ron Cooper appointed CEO and director effective July 22, 2024; Jason Hanson resigns but remains as strategic advisor.
- Cooper receives $700k base salary, 60% bonus target, and inducement option for 1.25M shares at $8.81, vesting over 4 years.
- Raj Pruthi promoted to CMO succeeding Richard Bryce, who departed July 19, 2024.
- Hanson's transition amendment provides $390k severance payment; retains consulting role at $25k/month for 6 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312524183292/0001193125-24-183292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312524183292/d597787d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-183292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer